Ekso Bionics Holdings Inc (NASDAQ:EKSO) Associates With HASOMED To Introduce Functional Electrical Stimulation For The EksoGT™ Exoskeleton


Ekso Bionics Holdings Inc (NASDAQ:EKSO) reported the release of the EksoGT™ exoskeleton’s FES interface capability via an association with HASOMED. Previously applied for research, HASOMED’s RehaStim2 FES addition with EksoGT exoskeleton is CE Marked and is now offered for routine clinical application in Europe.

The details

Thomas Looby, the CEO and President of Ekso, reported that they strategically work to enhance patient outcome by continually transforming rehabilitation with their exoskeleton technology. The integration of the EksoGT and its advantages, with the RehaStim2 FES know-how, offers clinicians with the latest developments in care, which eventually enhances patient quality of life and clinical outcomes. The synergies between these two know-how mark a vital step in their ability to provide an even more versatile equipment that allows clinicians to offer rehabilitation to an extensive range of patients across varied disease states, including stroke and spinal cord injuries.

FES marks as a technique that utilizes low energy electrical pulses to falsely generate body movements in folks who are paralyzed due to damage to the CNS. Clinical practitioners in EMEA can buy RehaStim2 via HASOMED, or as an advancement, with training delivered by Ekso. The combination of FES and exoskeleton technology, give clinicians the synergistic advantages of earlier muscle stimulation and mobility to offer rehabilitation to a wider spectrum of patients, moving from almost independent to pre-ambulatory.

Matthias Weber, the Owner and CEO of HASOMED, reported that their RehaStim2 FES device transmits electrical impulses to the muscles, resulting in intended movement of extremities in spite of paralysis. Now, through their extended association with Ekso, European rehabilitation experts will have the prospect to offer advanced combination treatment to their patients. The introductory European customer deployment for the EksoGT exoskeleton together with RehaStim2 FES equipment is planned for next month, and is currently offered for investigational research application in the United States.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.